255 related articles for article (PubMed ID: 11475149)
41. Bone scintiscanning in osteolytic lesions.
Solav S
Clin Nucl Med; 2004 Jan; 29(1):12-20. PubMed ID: 14688592
[TBL] [Abstract][Full Text] [Related]
42. Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray.
Lindström E; Lindström FD
Acta Med Scand; 1980; 208(4):289-91. PubMed ID: 6449830
[TBL] [Abstract][Full Text] [Related]
43. [Technetium 99-m sestamibi bone scan in musculo-skeletal neoplasms].
Robinson D; Pinkas L; Mindlin L; Halperin N; Horn T
Harefuah; 1997 Dec; 133(11):509-14, 592. PubMed ID: 9451886
[TBL] [Abstract][Full Text] [Related]
44. Different patterns of technetium-99m sestamibi uptake in multiple myeloma.
Pace L; Catalano L; Pinto A; De Renzo A; Di Gennaro F; Califano C; Del Vecchio S; Rotoli B; Salvatore M
Eur J Nucl Med; 1998 Jul; 25(7):714-20. PubMed ID: 9662593
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
46. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
Alam MS; Takeuchi R; Kasagi K; Misaki T; Miyamoto S; Iida Y; Hidaka A; Konishi J
Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573
[TBL] [Abstract][Full Text] [Related]
47. Evaluating benign and malignant musculoskeletal lesions with radionuclide angiography and SPECT using Tc-99m MIBI.
Ishiyama K; Tomura N; Okada K; Nagasawa H; Sashi R; Sasaki K; Sato K; Watarai J
Clin Nucl Med; 2005 Sep; 30(9):598-603. PubMed ID: 16100476
[TBL] [Abstract][Full Text] [Related]
48. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy.
Catalano L; Pace L; Califano C; Pinto AM; De Renzo A; Di Gennaro F; Del Vecchio S; Fonti R; Salvatore M; Rotoli B
Haematologica; 1999 Feb; 84(2):119-24. PubMed ID: 10091409
[TBL] [Abstract][Full Text] [Related]
49. A prospective study comparing 99mTc-MIBI and 99mTc-MDP with 99mTc-DTPA for lung ventilation scintigraphy in pulmonary thromboembolism.
Evbuomwan O; Purbhoo K; Vangu MDT
Nucl Med Commun; 2018 Dec; 39(12):1103-1112. PubMed ID: 30216229
[TBL] [Abstract][Full Text] [Related]
50. Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma.
Koutsikos J; Athanasoulis T; Anagnostopoulos A; Velidaki A; Passadi M; Dimopoulos MA; Zerva C
J Nucl Med; 2005 Jun; 46(6):978-82. PubMed ID: 15937309
[TBL] [Abstract][Full Text] [Related]
51. Tc-99m sestamibi scintigraphy in multiple myeloma.
Di Gennaro F; Catalano L; Pace L; de Renzo A; Pinto AM; del Vecchio S; Rotoli B; Salvatore M
Clin Nucl Med; 1999 Feb; 24(2):115-6. PubMed ID: 9988070
[TBL] [Abstract][Full Text] [Related]
52. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
[TBL] [Abstract][Full Text] [Related]
53. The use of 99mTc-MIBI scanning in multiple myeloma.
Tirovola EB; Biassoni L; Britton KE; Kaleva N; Kouykin V; Malpas JS
Br J Cancer; 1996 Dec; 74(11):1815-20. PubMed ID: 8956799
[TBL] [Abstract][Full Text] [Related]
54. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience.
Villa G; Balleari E; Carletto M; Grosso M; Clavio M; Piccardo A; Rebella L; Tommasi L; Morbelli S; Peschiera F; Gobbi M; Ghio R
J Exp Clin Cancer Res; 2005 Sep; 24(3):355-61. PubMed ID: 16270521
[TBL] [Abstract][Full Text] [Related]
55. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
[TBL] [Abstract][Full Text] [Related]
56. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
Sahin E; Zincirkeser S; Akcan AB; Elboga U
J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
[TBL] [Abstract][Full Text] [Related]
57. Differentiation of malignant and degenerative benign bone disease using Tc-99m MDP and Tc-99m citrate scintigraphy.
Sharma R; Mondal A; Bhatnagar A; Chakravarty KL; Mishra P; Chopra MK; Rawat HS; Kashyap R
Clin Nucl Med; 1998 Nov; 23(11):758-63. PubMed ID: 9814564
[TBL] [Abstract][Full Text] [Related]
58. Testicular lymphoma with bone/bone marrow metastases illustrated by scrotal sonography, spinal MRI, and total body Tc-99m HMDP and Tc-99m MIBI images.
Shih WJ; Kwolek DS; Lahr B
Ann Nucl Med; 1999 Oct; 13(5):293-7. PubMed ID: 10582797
[TBL] [Abstract][Full Text] [Related]
59. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules.
Mezosi E; Bajnok L; Gyory F; Varga J; Sztojka I; Szabo J; Galuska L; Leovey A; Kakuk G; Nagy E
Eur J Nucl Med; 1999 Aug; 26(8):798-803. PubMed ID: 10436190
[TBL] [Abstract][Full Text] [Related]
60. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.
Mosci C; Pericole FV; Oliveira GB; Delamain MT; Takahashi MES; Carvalheira JBC; Etchebehere ECSC; Santos AO; Miranda ECM; Lima MCL; Amorim BJ; de Souza CA; Lorand-Metze I; Ramos CD
Nucl Med Commun; 2020 Oct; 41(10):1081-1088. PubMed ID: 32732603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
